Last updated on November 2017

A study investigating the effect of crenezumab infusion on Alzheimer's disease progression in individuals with prodromal or mild Alzheimer's disease.


Brief description of study

Study Description:

CREAD2 is a Phase 3 study investigating the effect of an investigational drug in the form of an infusion on Alzheimer's disease progression in individuals with prodromal to mild Alzheimer's disease. The study drug, crenezumab, is a monoclonal antibody that targets amyloid-beta proteins in the brain. The study will last approximately two years.
Eligibility Criteria:
•50 to 85 years of age
•Experiencing recent memory problems
•Able to attend study visits at Sharp Mesa Vista Hospital's Clinical Research Center
•Have a caregiver (spouse, relative or health care aide) who spends at least 10 hours per week with the participant and can accompany the participant to study visits.

Other Details:

Participants are reimbursed for time and travel.

Clinical Study Identifier: TX133533

Contact Investigators or Research Sites near you

Start Over

Sharp Mesa Vista Hospital Clinical ...

Sharp Mesa Vista Hospital Clinical Research Center
San Diego, CA USA
  Connect »